GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (MEX:EXAS) » Definitions » Cyclically Adjusted Price-to-FCF

Exact Sciences (MEX:EXAS) Cyclically Adjusted Price-to-FCF : (As of Sep. 22, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Exact Sciences Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Exact Sciences Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Exact Sciences's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Cyclically Adjusted Price-to-FCF Chart

Exact Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Exact Sciences Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Exact Sciences's Cyclically Adjusted Price-to-FCF

For the Diagnostics & Research subindustry, Exact Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exact Sciences's Cyclically Adjusted Price-to-FCF Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Exact Sciences's Cyclically Adjusted Price-to-FCF falls into.



Exact Sciences Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Exact Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Exact Sciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=7.077/132.5538*132.5538
=7.077

Current CPI (Jun. 2024) = 132.5538.

Exact Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201409 -3.794 100.428 -5.008
201412 -5.900 99.070 -7.894
201503 -6.484 99.621 -8.627
201506 -6.833 100.684 -8.996
201509 -7.394 100.392 -9.763
201512 -6.819 99.792 -9.058
201603 -7.919 100.470 -10.448
201606 -7.490 101.688 -9.763
201609 -5.667 101.861 -7.375
201612 -5.623 101.863 -7.317
201703 -6.195 102.862 -7.983
201706 -7.403 103.349 -9.495
201709 -3.238 104.136 -4.122
201712 -6.060 104.011 -7.723
201803 -8.094 105.290 -10.190
201806 -8.788 106.317 -10.957
201809 -8.795 106.507 -10.946
201812 -8.433 105.998 -10.546
201903 -13.031 107.251 -16.105
201906 -7.709 108.070 -9.456
201909 -12.291 108.329 -15.039
201912 -9.024 108.420 -11.033
202003 -9.951 108.902 -12.112
202006 -4.327 108.767 -5.273
202009 9.952 109.815 12.013
202012 12.036 109.897 14.517
202103 -10.876 111.754 -12.900
202106 1.829 114.631 2.115
202109 -9.522 115.734 -10.906
202112 -9.988 117.630 -11.255
202203 -23.674 121.301 -25.870
202206 -14.172 125.017 -15.026
202209 -9.724 125.227 -10.293
202212 -2.288 125.222 -2.422
202303 -6.821 127.348 -7.100
202306 6.251 128.729 6.437
202309 -0.078 129.860 -0.080
202312 3.245 129.419 3.324
202403 -10.918 131.776 -10.982
202406 7.077 132.554 7.077

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exact Sciences  (MEX:EXAS) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Exact Sciences Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Exact Sciences's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Exact Sciences Business Description

Traded in Other Exchanges
Address
5505 Endeavor Lane, Madison, WI, USA, 53719
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.